Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer

This publication has 18 references indexed in Scilit:

• An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer
  Oncology, 2005
• Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
  British Journal of Cancer, 2005
• Nutritional Interventions in Cancer Prevention
  Journal of Clinical Oncology, 2005
• Pancreatic Cancer Registry in Japan
  Pancreas, 2004
• Phase II trial with S-1 in chemotherapy-naı̈ve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)
  European Journal of Cancer, 2003
• Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
  Oncology, 2000
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
  European Journal of Cancer, 1998
• Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
  Cancer Chemotherapy and Pharmacology, 1996
• Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
  Annals of Oncology, 1996
• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
  Anti-Cancer Drugs, 1996